CERVIRON®
CLINICALLY PROVEN EFFECTIVENESS IN TREATING GYNAECOLOGICAL DISORDERS
Four clinical trials have evaluated the performance and safety of CERVIRON® medical device administration.
The results of these studies have been published in prestigious journals available on the ScienceDirect platform and in Biomedical Reports. CERVIRON® has demonstrated clinical efficacy and a very high safety profile in more than 500 patients.
CERVIRON®
RESULTS AFTER THERE MONTHS OF TREATMENT:
CERVIRON®
CLINICAL EVIDENCE IN OVER 500 PATIENTS
CLINICAL STUDIES:
Multicentric Clinical Investigation to Evaluate the Performance and Safety of CERVIRON® Ovules in the Local Treatment of Non-Specificor Endogenous Symptomatic Vaginitis.
- Improvement ofvaginal symptoms > 72.34%
- Degree of satisfaction 95.74%
- Normal pH level> 100%
Conclusion: CERVIRON® can be used a standalone treatment in symptomatic, nonspecific vaginitis, significantly alleviates aerobic vaginitis symptoms while restoring the normal pH and reducing signs of vaginal inflammation. Administered once a day for a period of 15 consecutive days during 3 consecutive months, CERVIRON® is considered a safe and effective alternative to alleviate specific signs and symptoms of atrophic vaginitis (eg, dysuria, dyspareunia, and vaginal inflammation) in postmenopausal women, especially when hormonotherapy is not recommended.
The results of treatment with CERVIRON® have been published in the international scientific journal ScienceDirect .
🔗 Read and download the clinical study:
Clinical Performance and Safety of CERVIRON® Vaginal Ovules in the Management of Symptomatic Cervical Lesions
